Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal 4SCAR7U T Cell Therapy Targeting CD7-positive Hematological Malignancies
NCT05995028Phase 1Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Jul 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in t-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LBL), acute myeloid leukemia (AML) and 1 more, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of infusion at 6 months. Planned start Jun 2027; status: not yet recruiting.
02
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell acute lymphoblastic lymphoma (T-LBL)acute myeloid leukemia (AML)natural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT05995028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995028.